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To the Editor,
In a recent interesting monocentre, prospective study
published in the Turkish Journal of Medical Sciences, Bilgin
et al. found a prevalence of Helicobacter pylori (H. pylori)
antibodies (both IgM and IgG) significantly higher among
systemic sclerosis (SSc) patients (73.3%) than in controls
(46.6%) (P < 0.05) (1).
In the latest two decades, several studies have reported
potential links between chronic H. pylori infection and a
variety of extragastric manifestations; these include ischemic
heart disease, liver diseases, skin diseases, rheumatic diseases,
blood disorders, and others (2).
Although the etiology of SSc remains uncertain, it has
been reported that viral or bacterial infections can trigger
autoimmune diseases. Some researchers have suggested that
the production of specific autoantibodies in SSc patients is
the result of an antigen-driven response caused by molecular
mimicry (3) and the endothelial cells may be infected by
bacteria that may be instrumental in inducing vasculitis,
hence the importance of looking for infectious causal
mechanisms.
The findings of the study by Bilgin et al. (1) and the
conflicting results in the literature (4,5) deserve attention. It
is crucial to avoid selection biases. In particular, defining the
control group is a key step in planning and conducting a study.

Final Version: 17.11.2016

The control group is used to compare the history of exposure
in the cases with that in individuals who are free of the
study disease. Individuals selected as controls should not
only be free of the study disease, but should also be similar
to the cases in regards to past potential for exposure. Stated
somewhat differently, controls should be comparable to
the cases in the sense that both groups would have been
at equal risk of exposure if there were no disease-exposure
association (6). H. pylori infection is associated with low
socio-economic conditions and this should be taken into
account when the control populations are selected (7). In
assessing socio-economic status, its broad nature and the
variety of elements that it includes should be recognised.
Hence, such studies would require socially homogeneous
populations to minimise confounding factors.
This information is not reported in the paper by Bilgin
et al. (1); moreover, the authors reported a prevalence of H.
pylori infection in the controls of only 46.6%, diagnosed by
antibodies to H. pylori in serum, markers of exposure, and
not necessarily of true infection, while in the literature (8)
in Turkey H. pylori prevalence is very high, with a weighted
overall prevalence of 82.5% tested with the urea breath
test, able to diagnose the direct presence of the bacterium.
In conclusion, Bilgin et al. should report details about
the control groups; this could enrich their findings.
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To The Editor;
We thank Dr Ribaldone for his interest in our article
entitled “The prevalence of infectious agents in patients
with systemic sclerosis” regarding the evaluation of the
association between past and recent infections and the
etiology of systemic sclerosis (1). We agree with his opinion
that the control group should be similar to the cases in
regards to past potential for exposure. In our study, the
control group was similar to the study group in terms of
age and sex. We conducted the study in the central parts
of Turkey. However, we did not take into account socioeconomic status when both groups were determined.
The prevalence of H. pylori infection differs among
developing and developed countries. The prevalence of

H. pylori infection is not more than 10% in developed
countries, whereas it may reach up to 75%–80% in
developing countries. In the studies carried out in different
areas of Turkey, the rates of H. pylori positivity were found
by Kesli et al. (2) to be 36.9%, by Us et al. (3) 53%, by
Kaklıkaya et al. (4) 58.6%, and by Erzin et al. (5) 86%. In
our study, the prevalence of H. pylori antibodies was 73.3%
in SSc patients and 46.6% in the control group.
The infection prevalence alone should not be expected
to provide adequate evidence for or against a pathological
role in SSc. Thus, additional factors such as coinfections,
and immunological and genetic host factors will have to be
further identified and controlled to understand the role of
infectious agents in SSc.
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